Detail of "2075-46-9"

Reference

Mutagenicity study on pyrazole, seven pyrazole derivatives, and two nitroimidazoles with the L-arabinose resistance test of Salmonella typhimurium

Mutagenicity study on pyrazole, seven pyrazole derivatives, and two nitroimidazoles with the L-arabinose resistance test of Salmonella typhimurium. Alejandre-Duran, Encarnacion; Ruiz-Rubio, Manuel; Claramunt, Rosa M.; Lopez, Concepcion; Pueyo, Carmen (Fac. Cienc., Univ. Cordoba, Cordoba, Spain). Environ. Mutagen., 8(4), 611-19 (English) 1986. 443-48-1 and 14531-55-6 are cas registry numbers. These chemicals are also mentioned in this article. CODEN: ENMUDM. ISSN: 0192-2521. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Section cross-reference(s): 4 The mutagenicity of pyrazole (I) [288-13-1] and 7 I derivs. (4-nitropyrazole [2075-46-9], 4-bromopyrazole [2075-45-8], 1-methyl-4-nitropyrazole [3994-50-1], 3,5-dimethyl-4-nitropyrazole [14531-55-6], 1-methyl-4-bromopyrazole [15803-02-8], 4,4'-dinitro-1,1'-methylenedipyrazole [86111-62-8], and 4,4'-dibromo-1,1'-methylenedipyrazole [86111-61-7]) was investigated with the L-arabinose forward mutation assay of S. typhimurium. Two nitroimadazoles (1-methyl-5-nitroimidazole [3034-42-2] and metronidazole [443-48-1]) were included as ref. drugs. The mutagenicity of each chem. was detd. by both preincubation and liq. tests, in the presence or absence of S9 microsomal fraction. The mutagenic response was expressed as the abs. no. of L-arabinose-resistant mutants growing in selective plates, supplemented with traces of D-glucose. Strain BA13 with a wild-type lipopolysaccharide barrier was used as a comparison to the deep rough deriv. BA9. No mutagenic effect was detected with I and 2 of its derivs., 1-methyl-4-bromopyrazole and 4,4'-dibromo-1,1'-methylenedipyrazole. The other 5 I derivs. were mutagenic to different degrees, although their mutagenic potencies were always considerably lower than those of the 2 nitroimidazoles. 4-Nitropyrazoles, as well as 4,4'-dinitro-1,1'-methylenedipyrazoles are promising as alternatives to, or even substitutes for, the currently used nitroimidazoles. .

Preparation of 7-substituted aminopyrazolo[4,3-b]pyridines for use as antiinflammatory and antiallergic agents

Preparation of 7-substituted aminopyrazolo[4,3-b]pyridines for use as antiinflammatory and antiallergic agents.Several substances are used for example 156-87-6 and 2075-46-9 which are their cas registry numbers. (Beecham Group PLC, UK). Austrian AT 382377 B 25 Feb 1987, 17 pp. (Austria) CODEN: AUXXAK. CLASS: ICM: C07D471-04. ICA: A61K031-44. APPLICATION: AT 85-2047 10 Jul 1985. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) Section cross-reference(s): 28 The title compds. (I; Q = NR2CR3R4R5; R1 = H, (substituted) C1-6 alkyl, substituted Ph; R2 = H, C1-6 alkyl; R3 = substituted C2-10 alkenyl, substituted C1-10 alkyl; R4, R5 = H, C1-4 alkyl; R6 = H, C1-4 alkyl, or CH2Ph attached to one of the pyrazole N atoms; R7 = H) are prepd. as inflammation inhibitors and allergy inhibitors. I (R1 = Me; R6 = 1-H; R7 = H; Q = NHCH2CH:CH2) (II) (200 mg topically) provided 88% inhibition of ear edema in mice produced by topical application of 25 mg cantharidin. II was prepd. by condensation of 4-aminopyrazole with Et acetoacetate, cyclization of the product to 1,4-dihydro-5-methylpyrazolo[4,3-b]pyridin-7-one, conversion with POCl3 to 7-chloro-5-methyl-1H-pyrazolo[4,3-b]pyridine, and condensation with allylamine. .